Burning Rock Dx(US:BNR)2021-03-11 19:032020 Recap - The company completed 273,000 cumulative tests, with 72,000 tests completed in-hospital[8] - The company experienced a 33% year-over-year (YoY) revenue growth in 2H20 and a 43% gross profit growth[8] - Central-lab revenue increased by 26% in 2H20, with 44% of tests being blood-based during 2020[8] - In-hospital revenue increased by 63% in 2H20, with 29 contracted hospitals for reagent kits, an increase of 10 during 2020[8] Early Detection - The company completed the product development of a 6-cancer test and initiated early access[8] - The company's 6-cancer test covers 49% of China's urban cancer incidence by cancer type[29] - The 6-cancer test validation cohort showed 983% specificity and 806% sensitivity[23] Liquid Biopsy Therapy Selection - The company's OncoCompass Target kit & software passed the typing test in October 2020 and a concordance study is planned for 2H2021[42] - High reproducibility for variants with VAF above 05% was observed in liquid biopsy results[41] Financials - The company's revenue in 2020 was RMB 4299 million, a 13% increase YoY[48] - Gross profit in 2020 was RMB 3139 million, a 15% increase YoY[48] - The company projects 2021 revenue to be RMB 610 million[48]